Victrex PLC
04 October 2007
Thursday 4 October 2007
Victrex plc
Annual Trading Update
and
Completion of second VICTREX(R) PEEK(TM) polymer plant
Annual Trading Update
The Company announces its trading update for the year ended 30 September 2007.
We expect profits for the year to be in line with analysts' expectations with
record annual sales volume and better than expected second half margins.
Sales volume for the year grew by 7% to approximately 2,508 tonnes (2006: 2,339
tonnes). Second half sales volume of around 1,222 tonnes was in line with the
previous second half (1,226 tonnes) but 5% down on the first half (1,286 tonnes)
. However, group sales volume in August and September increased to levels
similar to those achieved in the first half.
•United States full year sales volume of 791 tonnes was 9% up on the
previous year (724 tonnes). Second half sales volume of 402 tonnes was up 3%
from 389 tonnes in the first half.
•Asia-Pacific sales volume of 474 tonnes for the year was up 13% on 2006
(419 tonnes). Second half sales volume of 233 tonnes was in line with the
record first half performance of 241 tonnes.
•At 1,243 tonnes, European sales volume was 4% up on the previous year
(1,196 tonnes) although second half sales volume of 587 tonnes was 11% down
on the strong first half of this year (656 tonnes). This was largely due to
reduced electronics sales, principally to European processors for use in
Asia-Pacific applications.
•Full year revenue of Invibio(R), our biomaterial business, grew by 25% to
approximately £19.2m, compared with last year (£15.4m). As expected, second
half revenue was in line with the first half of £9.5m.
Looking ahead, we continue to see opportunities to increase our sales volume and
remain confident in the fundamentals underlying the business. Consequently, we
look forward to further progress being made.
The announcement of the Company's results for the year ended 30 September 2007
will be made on Tuesday, 11 December 2007.
Completion of second VICTREX(R) PEEK(TM) polymer plant
Victrex also announces the completion of construction of its second VICTREX PEEK
polymer powder plant at a capital cost of approximately £32m, which will be
depreciated over its estimated useful life of 30 years. The plant has the
capacity to support a further 1,450 tonnes per annum of VICTREX PEEK sales and
is expected to be fully operational by the end of the year.
As previously reported, we have also commenced the uprate of the BDF supply
chain (our key raw material) to support this additional polymer capacity at an
estimated capital cost of £23m with completion expected in autumn 2008.
-Ends-
For further information please contact:
Victrex plc 01253 897700
Michael Peacock, Finance Director
Hogarth Partnership Limited 0207 357 9477
Nick Denton / Barnaby Fry
Victrex plc is an innovative world leader in high performance materials through
the manufacture of VICTREX(R) PEEK(TM) polymer, a high performance, easy to process
thermoplastic.
VICTREX PEEK has a unique combination of chemical, wear, electrical, hydrolysis
and temperature resistance, as well as excellent dimensional, mechanical and
chemical stability combined with inherent purity and low flammability.
End users specify VICTREX PEEK to reduce systems costs, improve part
performance, exploit greater design freedom and create a differentiated
application. VICTREX PEEK is used across a broad range of applications in
diverse markets including transport, industrial, electronics and medical.
Invibio(R), Victrex's biomaterial business, provides specialised solutions for
medical device manufacturers.
The Group's headquarters are in the UK where its manufacturing facilities are
based. This is complemented by a global network of sales, distribution and
technical centres that serve more than 30 countries worldwide.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.